Although there are many studies on targeted drugs for gastric cancer, only anti-HER2 drugs such as trastuzumab and anti-angiogenic pathway drugs such as apatinib are currently used in clinical practice (5, 6). This evidence concerns the gene ERBB2 and gastric cancer.